| abstract |
The present disclosure relates to methods for treating lichen planus (e.g., lichen planopilaris, mucosal lichen planus, cutaneous lichen planus) using Interleukin (IL)-17 antagonists, e.g., secukinumab. Also disclosed herein are IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating patients having lichen planus (e.g., lichen planopilaris, mucosal lichen planus, cutaneous lichen planus), as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods. |